A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB

The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we have measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Tringali, Giuseppe, Vollono, Catello, Calabresi, Paolo, Navarra, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579961/
https://www.ncbi.nlm.nih.gov/pubmed/33087040
http://dx.doi.org/10.1186/s10194-020-01193-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579961/
https://www.ncbi.nlm.nih.gov/pubmed/33087040
http://dx.doi.org/10.1186/s10194-020-01193-4

Ejemplares similares